Acute Kidney Injury in Myeloma Patients
Biomarkers of AKI in Patients with Multiple Myeloma Receiving Daratumumab: a Pilot Study
What will happen during the trial?
The aims of the study are:
To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy.
To establish whether these biomarkers serve to aid in early detection and prevention of AKI
Participants will give urine and blood samples at their normally scheduled lab appointments.
More Information
- Trial Status
- Accepting patients
- Enrollment
- 20 patients (estimated)
- Sponsors
- Brigham and Women's Hospital
- Collaborators
- Janssen Pharmaceuticals
- Trial Type
- Observational
- Last Update
- 3 months ago
- SparkCures ID
- 2058
- NCT Identifier
- NCT06549634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.